HomeAuthorsPosts by Sam Atkinson

Sam Atkinson

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge in profit for the third quarter ended May 31, 2026. This performance marks a decisive shift from a period of recovery toward a new phase of resilient growth in the...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the country grapples with a growing burden of non-communicable diseases (NCDs), particularly diabetes and chronic kidney disease. Recent estimates show that one-in-six Malaysians has diabetes, while one-in-seven is at risk of chronic...
spot_img

Keep exploring

SGX-LISTED COMPANIES

How AI And A Mandatory Migration Powered VICOM’s $167M Record FY2025

For most Singaporeans, the name VICOM evokes the rhythmic hum of a Sin Ming...
SGX-LISTED COMPANIES

SIA Engineering’s Massive $41.9M Profit In Q3 FY2025-26

How SIAEC is Defying Supply Chain Headwinds to Anchor the APAC Recovery While the spotlight...
SGX-LISTED COMPANIES

Why OTS Holdings Is Betting Big Despite A Swing To The Red In 1H 2026

A Tale of Two Semesters In the volatile food manufacturing sector, a single year can...
SGX-LISTED COMPANIES

StarHub Is Entering What Leadership Calls The “Harvest” Phase – FY2025

5 Things We Learned from StarHub’s FY2025 Results The modern telecommunications landscape is defined by...
SGX-LISTED COMPANIES

Oiltek International’s FY2025 Profits Come From Turning Waste Into Fuel

Introduction: The Paradox of Modern Energy In the global industrial theater, few challenges are as...
SGX-LISTED COMPANIES

First Ship Lease Trust’s Zero Debt & Paper Profits – FY2025

The Debt-Free Dilemma: Why FSL Trust’s 2025 Profit Milestone Left Unitholders with an Empty...
SGX-LISTED COMPANIES

Zhongxin Fruit & Juice Demonstrates Remarkable Operational Resilience In HY2025

The Big Squeeze: 5 Surprising Takeaways from Zhongxin Fruit’s Latest Financial Report Introduction: For most consumers,...
SGX-LISTED COMPANIES

The Secret Behind Wing Tai’s 300% Surge In HY2025

What Wing Tai’s Half-Year Results Reveal About the Property Market Financial statements are the forensic...
SGX-LISTED COMPANIES

Noel Gifts Slashes Losses By 95% While Core Business Retreats In 1H FY2026

The Art of the Narrow Escape In the high-stakes theater of corporate gifting, sentiment is...
SGX-LISTED COMPANIES

iX Biopharma’s Secret Shortcut To The US Medical Market – 1H FY2026

From Cash Burn to Bioavailability: How iX Biopharma Slashed Losses by 67% via a...
SGX-LISTED COMPANIES

Elite UK REIT Secured A Massive Government Payday In FY2025

Sovereign Shields and Strategic Pivots: Why Elite UK REIT’s 5.6% DPU Growth is a...
SGX-LISTED COMPANIES

DBS Record Profit Masks Q4 2025 Rate Squeeze

The $8 Billion Dividend Paradox: What DBS’s 2025 Results Reveal About the Future of...
Load more

Latest articles

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...